drugset / Trial / NCT01135329
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to learn more about reduced-intensity bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative. The main goal of the study is to determine how quickly the donor's bone marrow "takes" in your body. Other goals include describing how many people accept the bone marrow and how quickly the blood counts come up; describing Graft-versus-host disease (GVHD) and other complications; and describing how many people survive without progressive cancer and survive overall
Timeline
- Start
- 2010-08
- Primary completion
- 2012-05
- Completion
- 2012-05
Outcome
Outcome not reported
Stopped: “The stopping rule was met and hence the study was closed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Busulfan | Small molecule | 0.8 mg/kg | Oral |
| Background | Busulfan | Small molecule | 1 mg/kg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Background | Tacrolimus | Small molecule | 1 mg | Intravenous |